Menu Philippe sold $28K of SOPH
Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $5.66 on 2026-07-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the specific open-market sale size, price, and total value, but it is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight.
Market read
Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional company-specific catalysts.
What to watch
The article provides no context on whether the sale was part of a larger scheduled program, nor any concurrent operational updates, limiting inference.
Background
The article is a SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by its Chief Medical Officer.
Ticker impact
SOPHiA GENETICS Form 4 shows CMO Menu Philippe sold 5,000 shares on 2026-07-27 at $5.6611, totaling $28,305.50.
Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.
The filing is an insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and the disclosed value is modest relative to typical market-moving thresholds.
Market effects
Minimal. No sector-wide regulatory, clinical, or commercial update is disclosed.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still watch for follow-on disclosures.
Key entities
- issuerSOPHiA GENETICS SA
Company whose Form 4 insider transaction is disclosed.
- insiderMenu Philippe
Chief Medical Officer who sold 5,000 shares.
